Literature DB >> 7288173

Frequency of naturally occurring antibody to influenza virus antigenic variants selected in vitro with monoclonal antibody.

A Natali, J S Oxford, G C Schild.   

Abstract

Antigenic variants of A/Texas/77 (H3N2) virus were selected in vitro using monoclonal antibody to virus haemagglutinin (HA). The antigenic variants and parental A/Texas/77 viruses were used to to evaluate the frequency of anti-HA antibodies in the sera of children and adults using single-radial-haemolysis (SRH) tests. Twenty to 41% of selected sera from adults, which contained antibody to the parental A/Texas/77 virus, failed to react with the different antigenic mutant viruses. A higher proportion of sera from children (37-58%) failed to react with the antigenic variants. Certain human sera and particularly those of children would appear to possess a more limited antibody repertoire to influenza HA, potentially allowing new antigenic variants to escape neutralization and spread in the community.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288173      PMCID: PMC2134050          DOI: 10.1017/s0022172400069394

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  10 in total

1.  The mechanism of antigenic drift in influenza virus: sequence changes in the haemagglutinin of variants selected with monoclonal hybridoma antibodies.

Authors:  W G Laver; G M Air; R G Webster; W Gerhard; C W Ward; T A Dopheide
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1980-02-25       Impact factor: 6.237

2.  Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection.

Authors:  J S Oxford; L R Haaheim; A Slepushkin; J Werner; E Kuwert; G C Schild
Journal:  J Hyg (Lond)       Date:  1981-02

3.  Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule.

Authors:  J W Yewdell; R G Webster; W U Gerhard
Journal:  Nature       Date:  1979-05-17       Impact factor: 49.962

4.  Influenza immunization policies and practices in Japan.

Authors:  W R Dowdle; J D Millar; L B Schonberger; F A Ennis; J R LaMontagne
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

5.  Genetic dimorphism in influenza viruses: characterization of stably associated hemagglutinin mutants differing in antigenicity and biological properties.

Authors:  E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

6.  Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza.

Authors:  G C Schild; M S Pereira; P Chakraverty
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

7.  Haemagglutination-inhibition antibodies in human sera to an antigenic mutant of influenza A/Texas/1/77 (H3N2) virus obtained in vitro.

Authors:  L R Haaheim
Journal:  Acta Pathol Microbiol Scand B       Date:  1980-12

8.  Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies.

Authors:  W G Laver; W Gerhard; R G Webster; M E Frankel; G M Air
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

9.  Production of antibodies against influenza virus by somatic cell hybrids between mouse myeloma and primed spleen cells.

Authors:  H Koprowski; W Gerhard; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

10.  Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies.

Authors:  W Gerhard; R G Webster
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

  10 in total
  13 in total

1.  An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin.

Authors:  L E Brown; J M Murray; D O White; D C Jackson
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Identifying antigenicity-associated sites in highly pathogenic H5N1 influenza virus hemagglutinin by using sparse learning.

Authors:  Zhipeng Cai; Mariette F Ducatez; Jialiang Yang; Tong Zhang; Li-Ping Long; Adrianus C Boon; Richard J Webby; Xiu-Feng Wan
Journal:  J Mol Biol       Date:  2012-05-17       Impact factor: 5.469

3.  Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites.

Authors:  K V Coelingh; C C Winter
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 4.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 5.  The use of monoclonal antibodies in virology.

Authors:  J Oxford
Journal:  J Hyg (Lond)       Date:  1982-06

Review 6.  Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift.

Authors:  Meghan O Altman; Davide Angeletti; Jonathan W Yewdell
Journal:  Viral Immunol       Date:  2018-01-22       Impact factor: 2.257

7.  Use of monoclonal anti-haemagglutinin antibodies for the "in vitro" selection of a sequential influenza virus antigenic variant.

Authors:  A Natali; C Chezzi
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

8.  Human sera possess a limited antibody repertoire to influenza neuraminidase antigenic variants selected in vitro.

Authors:  A Natali; P F Panizzi; C Chezzi; J S Oxford
Journal:  J Hyg (Lond)       Date:  1984-04

9.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.

Authors:  M L Wang; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.